In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Plays Hardball With Hep C Patient Assistance

Executive Summary

Gilead Sciences recently began limiting enrollment in its Sovaldi and Harvoni patient assistance program in an attempt to pressure payors to expand their coverage criteria. The big question is how payors are likely to react.

You may also be interested in...



Pharma Survival In A Transforming Global Payer Environment

Economic pressures and technological advances are forcing an unprecedented transformation of the payer environment. Biopharma companies must adjust their market access and pricing strategies to maintain competitively well-positioned and profitable organizations.

The Shrinking Value Of Best-In-Class And First-In-Class Drugs

Incumbency ain’t worth what it once was. Pharma companies are spending billions to create advantages that won’t have significant lasting power. Smart followers can do as well – for less.

Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process And For Consumers

“Nonprescription Drug Product with an Additional Condition” for OTC use proposed rule would add to drug firms’ workloads for some OTC switches. Along with NDAs, sponsors would need to show a DFl isn’t sufficient to ensure a consumer can appropriately self-select and use a drug OTC and how an “additional condition” system would work.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

IV004426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel